163 related articles for article (PubMed ID: 20359855)
1. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation.
Quan ZW; Yang Y; Li JY; Gong W; Qin YY; Li SG
Biomed Pharmacother; 2010 Sep; 64(7):451-7. PubMed ID: 20359855
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line].
Qin YY; Li JY; Li SG; Yue JN; Quan ZW
Zhonghua Wai Ke Za Zhi; 2008 Mar; 46(5):381-3. PubMed ID: 18785538
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
[TBL] [Abstract][Full Text] [Related]
5. [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration].
Gong W; Qin YY; Li SG; Quan ZW; Li JY; Zhuang PY; Wan ZW
Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2718-22. PubMed ID: 21162905
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of ICBP90 contributes to doxorubicin resistance.
Wang J; Song Y; Xu S; Zhang Q; Li Y; Tang D; Jin S
Eur J Pharmacol; 2011 Apr; 656(1-3):33-8. PubMed ID: 21296067
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Washiro M; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Sugimoto T; Seki N; Miyazaki M
J Cancer Res Clin Oncol; 2008 Jul; 134(7):793-801. PubMed ID: 18204862
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):72-80. PubMed ID: 17287171
[TBL] [Abstract][Full Text] [Related]
9. The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma.
Li JY; Quan ZW; Zhang Q; Liu JW
BMC Cancer; 2007 Jul; 7():125. PubMed ID: 17617924
[TBL] [Abstract][Full Text] [Related]
10. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines.
Lee TK; Lau TC; Ng IO
Cancer Chemother Pharmacol; 2002 Jan; 49(1):78-86. PubMed ID: 11855756
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.
Fan YZ; Zhao ZM; Fu JY; Chen CQ; Sun W
Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):414-22. PubMed ID: 20688607
[TBL] [Abstract][Full Text] [Related]
13. Liensinine induces gallbladder cancer apoptosis and G2/M arrest by inhibiting ZFX-induced PI3K/AKT pathway.
Shen Y; Bian R; Li Y; Gao Y; Liu Y; Xu Y; Song X; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2019 Jun; 51(6):607-614. PubMed ID: 31074773
[TBL] [Abstract][Full Text] [Related]
14. Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
Rouibah H; Kebsa W; Lahouel M; Zihlif M; Ahram M; Aburmeleih B; Mustafa E; Al-Ameer HJ
Anticancer Agents Med Chem; 2018; 18(3):375-387. PubMed ID: 29318976
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
16. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells.
Saffi J; Agnoletto MH; Guecheva TN; Batista LF; Carvalho H; Henriques JA; Stary A; Menck CF; Sarasin A
DNA Repair (Amst); 2010 Jan; 9(1):40-7. PubMed ID: 19926538
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.
Fouad MA; Sayed-Ahmed MM; Huwait EA; Hafez HF; Osman AM
BMC Pharmacol Toxicol; 2021 Jan; 22(1):8. PubMed ID: 33509300
[TBL] [Abstract][Full Text] [Related]
18. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
[TBL] [Abstract][Full Text] [Related]
19. Low-dose doxorubicin with carotenoids selectively alters redox status and upregulates oxidative stress-mediated apoptosis in breast cancer cells.
Vijay K; Sowmya PR; Arathi BP; Shilpa S; Shwetha HJ; Raju M; Baskaran V; Lakshminarayana R
Food Chem Toxicol; 2018 Aug; 118():675-690. PubMed ID: 29920287
[TBL] [Abstract][Full Text] [Related]
20. MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma.
Wang W; Chen LC; Qian JY; Zhang Q
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9829-9839. PubMed ID: 31799650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
